Results 121 to 130 of about 233,161 (342)

Predicting Different Recurrence Risk in HNSCC Using Circulating Inflammatory and T‐Cell Biomarkers

open access: yesThe Laryngoscope, EarlyView.
ABSTRACT Objective Head and neck squamous cell carcinoma (HNSCC) lacks reliable prognostic circulating biomarkers, and the role of the immune system in its progression remains incompletely understood. This study aimed to evaluate the prognostic value of systemic inflammatory and immune biomarkers in surgically treated patients with primary oral cavity (
Riccardo Gili   +10 more
wiley   +1 more source

Hidroa vacciniforme y el desorden linfoproliferativo hidroa vacciniforme-like reporte de caso y revisión de la literatura

open access: yesRevista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica
Introducción: La hidroa vacciniforme es una fotodermatosis infrecuente crónica que puede relacionarse con la infección por el virus del Epstein-Barr. También, se asociada a deformidad progresiva y al riesgo de desarrollo de linfomas cutáneos. Método:
Ana María Gutiérrez-Delgadillo   +6 more
doaj   +1 more source

The Global Burden of Leukemia, 1990–2021: A Systematic Analysis of Prevalence, DALYs, and Risk Factors From the Global Burden of Disease Study

open access: yesMed Research, EarlyView.
Using data from the Global Burden of Disease Study 2021, we systematically assessed leukemia prevalence and disability‐adjusted life years (DALYs) across 204 countries and territories from 1990 to 2021, stratified by subtype, demographics, and risk factors.
Yuping Wu   +8 more
wiley   +1 more source

Niña con infección recurrente y severa de virus Epstein-Barr CD27 negativo. Reporte de caso

open access: yesRevista Alergia México, 2018
Antecedentes: La infección severa por virus de Epstein-Barr puede estar asociada con inmunodeficiencias y también predisponer a otras infecciones virales, bacterianas y fúngicas.
Ana Ivette Mondragón-Pineda
doaj  

Supplementary Figure 2 from Epstein–Barr Virus Serology as a Potential Screening Marker for Nasopharyngeal Carcinoma among High-Risk Individuals from Multiplex Families in Taiwan [PDF]

open access: gold, 2023
Anna E. Coghill   +10 more
openalex   +1 more source

Advances and Prospects of Stereotactic Radiosurgery and Stereotactic Ablative Body Radiotherapy: Evolving Paradigms in Precision Oncology

open access: yesMed Research, EarlyView.
The graphical abstract outlines the progressive development and impact of stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). Technological Evolution illustrates the transition from brachytherapy with single‐dose, LDR/HDR schedules to fractionated radiotherapy, three‐dimensional conformal radiotherapy (3DCRT) and Gamma Knife ...
Jing Zhang   +10 more
wiley   +1 more source

Epstein-Barr Virus–Associated Pulmonary Smooth Muscle Tumor After Lung Transplantation [PDF]

open access: bronze, 2015
Alexander A. Brescia   +4 more
openalex   +1 more source

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

open access: yesRheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen   +6 more
wiley   +1 more source

Tumour‐informed workflow to use ctDNA as a biomarker for risk of recurrence in head and neck cancer patients post‐treatment

open access: yesVIEW, EarlyView.
Our study presents a tumour‐informed circulating tumour DNA (ctDNA) workflow designed to enhance the detection of recurrence in head and neck cancer patients, addressing key challenges such as low ctDNA tumour fractions and tumour heterogeneity. Abstract Circulating tumour DNA (ctDNA) is a promising minimally invasive biomarker for monitoring treatment
Xiaomin Huang   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy